Strand V, Kaeley GS, Bergman MJ, Gladman DD, Coates LC, Sherif B, Hur P, Parikh B, Gilloteau I, Mease PJ. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomized phase 3 trial. Lancet Rheumatol. 2022 Mar 1;4(3):e208-19.
Davis KL, Kaye JA, Masters ET, Iyer S. Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib. Curr Oncol. 2018 Feb;25(1):e40-9. doi: 10.3747/co.25.3723
Augustin M, Krieger T, McBride D, Graham C, Melzer N, Kneidl J, Gutknecht M, Neidhardt K. Kosten-effektivität von secukinumab in der induktionstherapie der psoriasis in Deutschland. Poster presented at the 49th German Society of Dermatology (DDG) Conference; April 26, 2017. Berlin, Germany. [abstract] J Dtsch Dermatol Ges. 2017 Apr; 15(S1):130-1. doi: 10.1111/ddg.13213